Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial

Phase 0 Terminated 7 enrolled Milton S. Hershey Medical Center National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research is being done to find out if the study drug (posaconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

Timeline

Start: 2022-05-13
Primary completion: 2024-11-06
Completion: 2024-11-06

Outcome

Outcome not reported

Stopped (Enrollment): “The study was stopped due to slow accrual.”

Publications

Bhanja D, Neighbors J, Connor J, Zadeh G, Mansouri A. Neuropharmacological Study of Posaconazole for Glioblastoma: A Phase 0 Clinical Trial Protocol. Neurosurgery. 2022 Oct 1;91(4):658-665. doi: 10.1227/neu.0000000000002071. Epub 2022 Jul 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Posaconazole	Small molecule	300 mg	Oral